West Pharmaceutical Services, Inc. (WST) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

West Pharmaceutical Services, Inc. (WST) Healthcare & Pipeline Overview

West Pharmaceutical Services, Inc. provides critical containment and delivery solutions for injectable drugs, serving biologic, generic, and pharmaceutical companies worldwide. With a focus on innovative technologies and integrated solutions, WST operates through its Proprietary Products and Contract-Manufactured Products segments, ensuring drug quality and safe delivery.

What Is the Investment Thesis for WST?

West Pharmaceutical Services, Inc. presents a compelling investment case driven by its critical role in the injectable drug delivery market. The company's focus on innovative technologies, such as Crystal Zenith and self-injection devices, positions it to capitalize on the growing demand for advanced drug delivery solutions. With a market capitalization of $25.1B and a profit margin of 16.9%, WST demonstrates financial stability. Key growth catalysts include the increasing adoption of biologics and biosimilars, which require sophisticated containment and delivery systems. However, the company's high P/E ratio of 43.5 and beta of 1.15 indicate potential volatility and valuation concerns. Investors should monitor the company's ability to maintain its competitive edge and navigate regulatory landscapes to fully realize its growth potential.

Based on FMP financials and quantitative analysis

WST Key Highlights

• Market Cap of $25.1B reflects West Pharmaceutical Services, Inc.'s significant presence in the medical instruments and supplies industry.
• P/E ratio of 43.5 indicates a premium valuation, suggesting investor expectations of future growth.
• Profit Margin of 16.9% demonstrates the company's ability to generate earnings from its revenue.
• Gross Margin of 36.2% highlights the efficiency of West Pharmaceutical Services, Inc.'s production and service delivery.
• Dividend Yield of 0.27% provides a modest income stream for investors.

Who Are WST's Competitors?

WST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are WST's Key Strengths?

• Strong market position in injectable drug containment and delivery.
• Proprietary technologies and innovative product offerings.
• Established relationships with major pharmaceutical companies.
• Global distribution network and regulatory expertise.

What Are WST's Weaknesses?

• High P/E ratio indicating potential overvaluation.
• Dependence on the pharmaceutical industry's R&D pipeline.
• Exposure to raw material price fluctuations.
• Limited presence in emerging markets compared to some competitors.

What Could Drive WST Stock Higher?

• Increasing demand for injectable drugs and biologics driving revenue growth.
• Potential regulatory approvals for new drug delivery systems.
• Expansion of manufacturing capacity to meet growing demand.
• Strategic partnerships and acquisitions to enhance product portfolio.

What Are the Key Risks for WST?

• Rich valuation — a P/E of 43.5 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Intense competition from established and emerging players.
• Stringent regulatory requirements and potential delays in approvals.
• Product liability claims and recalls.
• Economic downturns affecting pharmaceutical R&D spending.

What Are the Growth Opportunities for WST?

• Expansion in Biologics and Biosimilars: The increasing adoption of biologics and biosimilars presents a significant growth opportunity for West Pharmaceutical Services, Inc. These complex drugs require advanced containment and delivery systems, driving demand for West's proprietary products like Crystal Zenith vials and self-injection devices. The global biologics market is projected to reach $420 billion by 2028, growing at a CAGR of 9.8%. West's expertise in this area positions it to capture a substantial share of this expanding market, enhancing its revenue and profitability.
• Growth in Self-Injection Devices: The market for self-injection devices is rapidly expanding, driven by the increasing prevalence of chronic diseases and the shift towards home healthcare. West Pharmaceutical Services, Inc. offers a range of self-injection devices that enhance patient convenience and adherence. The global self-injection device market is expected to reach $55.7 billion by 2031, growing at a CAGR of 9.8% from 2022 to 2031. By focusing on innovation and strategic partnerships, West can capitalize on this trend and strengthen its market position.
• Geographic Expansion in Asia Pacific: The Asia Pacific region represents a high-growth market for West Pharmaceutical Services, Inc., driven by increasing healthcare expenditure and a growing population. Expanding its presence in countries like China and India, where demand for advanced drug delivery systems is rising, offers substantial growth opportunities. The Asia Pacific pharmaceutical market is projected to reach $550 billion by 2030. West's strategic investments in this region can drive significant revenue growth and diversify its geographic footprint.
• Strategic Partnerships and Acquisitions: Forming strategic partnerships and pursuing targeted acquisitions can enhance West Pharmaceutical Services, Inc.'s product portfolio and market reach. Collaborating with pharmaceutical companies and medical device manufacturers can accelerate the development and commercialization of innovative drug delivery solutions. Identifying and acquiring companies with complementary technologies and market access can further strengthen West's competitive position and drive long-term growth. This proactive approach will enable West to stay ahead of market trends and capitalize on emerging opportunities.
• Focus on Integrated Solutions: West Pharmaceutical Services, Inc.'s integrated solutions, including analytical lab services, pre-approval primary packaging support, and regulatory expertise, provide a competitive advantage. These services enhance the value proposition for pharmaceutical companies, streamlining the drug development process and ensuring regulatory compliance. By expanding its integrated solutions offerings, West can strengthen its relationships with customers and drive recurring revenue. The market for pharmaceutical analytical testing is projected to reach $12.5 billion by 2027, growing at a CAGR of 8.5%.

What Opportunities Does WST Have?

• Expansion in biologics and biosimilars market.
• Growth in self-injection devices and home healthcare.
• Geographic expansion in Asia Pacific and other emerging markets.
• Strategic partnerships and acquisitions to enhance product portfolio.

What Threats Does WST Face?

• Intense competition from established and emerging players.
• Stringent regulatory requirements and potential delays in approvals.
• Product liability claims and recalls.
• Economic downturns affecting pharmaceutical R&D spending.

What Are WST's Competitive Advantages?

• Proprietary Technology: West's patented technologies, such as Crystal Zenith, provide a competitive edge in drug containment.
• Established Customer Relationships: Long-standing relationships with major pharmaceutical companies create a barrier to entry for competitors.
• Regulatory Expertise: Deep understanding of regulatory requirements ensures compliance and streamlines the drug development process for customers.
• Global Distribution Network: Extensive distribution network enables efficient delivery of products to customers worldwide.
• High Switching Costs: The critical nature of West's products in drug delivery creates high switching costs for customers.

What Does WST Do?

West Pharmaceutical Services, Inc., founded in 1923 and headquartered in Exton, Pennsylvania, is a global leader in the design, manufacture, and sale of containment and delivery systems for injectable drugs and healthcare products. The company operates through two primary segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a range of solutions, including stoppers and seals for injectable packaging, syringe and cartridge components, and advanced administration systems that enhance drug delivery through reconstitution, mixing, and transfer technologies. This segment also provides films, coatings, washing, vision inspection, and sterilization services to improve packaging component quality. West's drug containment solutions include Crystal Zenith, a cyclic olefin polymer used in vials, syringes, and cartridges, as well as self-injection devices and integrated solutions such as analytical lab services and regulatory expertise. The Contract-Manufactured Products segment focuses on the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. West serves pharmaceutical, diagnostic, and medical device companies across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, distributing its products through a combination of its sales force, distribution network, contract sales agents, and regional distributors.

What Products and Services Does WST Offer?

• Designs and manufactures containment systems for injectable drugs.
• Provides delivery systems for healthcare products.
• Offers stoppers and seals for injectable packaging.
• Supplies syringe and cartridge components.
• Develops administration systems for drug reconstitution and transfer.
• Offers films, coatings, washing, and sterilization services for packaging components.
• Provides drug containment solutions like Crystal Zenith vials and syringes.
• Manufactures self-injection devices.

How Does WST Make Money?

• Generates revenue through the sale of proprietary products like stoppers, seals, and syringe components.
• Offers contract-manufactured products, including devices used in surgical, diagnostic, and drug delivery systems.
• Provides integrated solutions, such as analytical lab services and regulatory expertise, to pharmaceutical companies.
• Distributes products through its sales force, distribution network, and contract sales agents.

What Industry Does WST Operate In?

West Pharmaceutical Services, Inc. operates within the medical instruments and supplies industry, which is characterized by technological advancements and stringent regulatory requirements. The industry is experiencing growth driven by the increasing demand for advanced drug delivery systems, particularly for biologics and personalized medicine. Competition includes companies like Quest Diagnostics Incorporated (DGX), STERIS plc (STE), and Labcorp Holdings Inc. (LH), each vying for market share through innovation and strategic partnerships. West's focus on injectable drug containment and delivery positions it favorably within this evolving landscape.

Who Are WST's Key Customers?

• Biologic drug companies requiring advanced containment and delivery systems.
• Generic drug companies seeking cost-effective packaging solutions.
• Pharmaceutical drug companies developing innovative injectable therapies.
• Medical device companies needing components for drug delivery systems.
• Diagnostic companies utilizing devices manufactured by West.

Company Profile

West Pharmaceutical Services, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Exton, US. The company is led by CEO Eric Green. WST has traded publicly since 1980.

ROE 19%Key Financial Metrics

Return on equity for West Pharmaceutical Services, Inc. stands at 18.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 13.9%, showing how much profit it generates from its asset base. WST trades at a trailing price-to-earnings ratio of 43.52, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.2%, the inverse of the P/E and a quick read on earnings relative to price.

WST Valuation & Market Position

With a $25.1B market cap, West Pharmaceutical Services, Inc. sits in the large-cap segment of the market. Relative to its peer group, WST's quantitative score of 95/100 is above the peer average of 76/100.

Quarterly Financial Performance: West Pharmaceutical Services, Inc.

Revenue for West Pharmaceutical Services, Inc. came in at $872.3M during Q2 2026, a 3.2% improvement versus the preceding quarter. The company recorded net income of $154.0M, with diluted EPS of $2.16. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, WST averaged $1.95 in diluted EPS.

F-Score 8/9Financial Health

West Pharmaceutical Services, Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 17.18 places it in the safe zone, indicating low near-term bankruptcy risk.

8/8 beatsEarnings Track Record

West Pharmaceutical Services, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 17.4% above estimates on average.

FY2026 estForward Outlook

Wall Street analysts project West Pharmaceutical Services, Inc. revenue of about $3.33B for fiscal 2026, with EPS near $8.62. The estimate reflects 12 contributing analysts.

Net buyingInsider Activity

Over the past six months, West Pharmaceutical Services, Inc. insiders filed 15 SEC Form 4 transactions — 4 sales and 11 purchases. On net that is roughly 6K shares acquired (about $68K) — insiders putting money in tends to read as conviction.

WST Financials

WST Latest News

WST Analyst Consensus

WST MoonshotScore

Latest West Pharmaceutical Services, Inc. Analysis

WST Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources